Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.

New fluorescent biosensors are provided for use in methods of detecting a ligand-induced hallucinogenic conformational change of a G Protein-Coupled Receptor (GPCR), detecting a hallucinogenic compound, detecting a non-hallucinogenic antidepressant compound, measuring the hallucinogenic potential of a compound, measuring the antipsychotic potential of a compound, and suitable kits thereof.

Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.

Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed.

The present invention provides a rapid method for forensic drug testing in a post-mortem individual using muscle tissue and fluid associated with the muscle tissue obtained from remains of the post-mortem individual. The method comprises obtaining muscle tissue and associated fluid from a post-mortem individual, collecting the fluid associated with the muscle tissue, analyzing the fluid associated with the muscle tissue to detect and quantify one or more non-naturally occurring drugs in the post-mortem individual, and identifying the one or more non-naturally occurring drugs in the post-mortem individual. The detection and quantification of non-naturally occurring drugs in muscle tissue and associated fluid is surprisingly faster than detection and quantification of the non-naturally occurring drugs in muscle tissue obtained from the same post-mortem individual and prepared as muscle tissue homogenates using the LC-MS/MS method, with results obtained in as soon as three hours.

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject or a live or a post-mortem animal using oral fluid collected from the post-mortem subject or live or post-mortem animal. The method comprises collecting a sample of oral fluid from a post-mortem subject or a live or a post-mortem animal, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal, and identifying the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.